Jing Li

6563186, May 13, 2003

Apr 10, 2002

10/119610

Jing Li - Cherry Hill NJ
Xiaoying Huang - Camden NJ

Rutgers, The State University - New Brunswick NJ

H01L 3100

257442, 257 40, 257642

Hybrid crystalline organic-inorganic quantum confined systems are disclosed, which contain alternating layers of a bifunctional organic ligand and a II-VI semiconducting chalcogenide, wherein the semiconducting chalcogenide layers contain chalcogenides have the formula MQ, in which M is independently selected from II-VI semiconductor cationic species and Q is independently selected from S, Se and Te; and the bifunctional organic ligands of each organic ligand layer are bonded by a first functional group to an element M of an adjacent II-VI semiconducting chalcogenide layer and by a second functional group to an element M from the adjacent opposing II-VI semiconducting chalcogenide layer, so that the adjacent opposing II-VI semiconducting chalcogenide layers are linked by the bifunctional organic ligands of the organic ligand layers. Optical absorption experiments show that these systems produce a significant blue shift in their optical absorption edges, 1. 2-1. 5 eV, compared to a shift of 1.

8507647, Aug 13, 2013

Dec 18, 2009

12/641465

Jing Li - Lansdale PA, US
Andre Lee Pearson - Somerville MA, US

Cubist Pharmaceuticals, Inc. - Lexington MA

C07K 11/02

530317, 514 24

The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against.

20140011998, Jan 9, 2014

Jul 3, 2013

13/934989

Jing Li - Lansdale PA, US

Millennium Pharmaceuticals, Inc. - Cambridge MA

C07F 5/04

544229, 546 13, 564 8

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

20140073558, Mar 13, 2014

Jun 12, 2013

13/916402

Jing Li - Lansdale PA, US
Andre Lee Pearson - Somerville MA, US

CUBIST PHARMACEUTICALS, INC. - Lexington MA

C07K 7/54

514 27, 530323, 514 211, 514 29

The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against

20200297860, Sep 24, 2020

Dec 4, 2019

16/702720

- Tokyo, JP
Xin Cheng - Wallingford PA, US
Daniel W. Custar - North Andover MA, US
Keiji Furuuchi - Wynnewood PA, US
Jing Li - Andover MA, US
Utpal Majumder - Andover MA, US
Toshimitsu Uenaka - West Chester PA, US

A61K 47/68
C07K 16/30
A61K 31/357
C07K 16/28
C07K 16/32

Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

20180193478, Jul 12, 2018

Feb 9, 2018

15/892921

- Tokyo, JP
Xin Cheng - Wallingford PA, US
Daniel W. Custar - North Andover MA, US
Keiji Furuuchi - Wynnewood PA, US
Jing Li - Andover MA, US
Utpal Majumder - Andover MA, US
Toshimitsu Uenaka - West Chester PA, US

A61K 47/68
C07K 16/28
C07K 16/32
A61K 31/357

Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

20180071412, Mar 15, 2018

Oct 4, 2017

15/724402

- Rahway NJ, US
Eric Hostetler - Collegeville PA, US
Thomas J. Greshock - Collegeville PA, US
Jing Li - Lansdale PA, US
Keith P. Moore - Doylestown PA, US
Idriss Bennacef - Ambler PA, US
James Mulhearn - Elkins PA, US
Harold Selnick - Ambler PA, US
Yaode Wang - Beijing, CN
Kun Yang - Beijing, CN
Jianmin Fu - Beijing, CN

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 51/04
C07D 519/00
C07D 471/04

The present invention is directed to pyrrolopyridine compounds of formula (I)or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

20170349611, Dec 7, 2017

Aug 18, 2017

15/680514

- Cambridge MA, US
Jing Li - Lansdale PA, US

C07F 5/02
C07K 5/065
C07K 5/06
C07K 5/08
C07F 5/04

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.